Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.46 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
| ▸ | JAK1 | P23458 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24840030 | 1.00 | PRMT5 (0.46) | PRMT5USP30HPGDSJAK1JAK2 | |
| SCHEMBL29189096 | 0.86 | JAK1 (0.42) | JAK1JAK2MEN1KMT2A | |
| SCHEMBL29189098 | 0.86 | JAK1 (0.42) | JAK1JAK2MEN1KMT2A | |
| SCHEMBL30718297 | 0.85 | PRMT5 (0.41) | PRMT5USP30HPGDSJAK1JAK2 | |
| SCHEMBL27292332 | 0.85 | PRMT5 (0.41) | PRMT5USP30HPGDSJAK1JAK2 | |
| SCHEMBL27292280 | 0.85 | PRMT5 (0.41) | PRMT5USP30HPGDSJAK1JAK2 | |
| SCHEMBL31091178 | 0.82 | PRMT5 (0.42) | PRMT5USP30HPGDSJAK1JAK2 | |
| SCHEMBL30994924 | 0.82 | MEN1 (0.40) | PRMT5USP30HPGDSJAK1JAK2 | |
| SCHEMBL29276231 | 0.82 | MEN1 (0.40) | PRMT5USP30HPGDSJAK1JAK2 | |
| SCHEMBL29276175 | 0.80 | PIK3CD (0.46) | PRMT5USP30HPGDSJAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327413-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2024-10-03 | — | — | US | disclosed |
| EP-4362946-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023278438-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327413-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | PRMT5 4242/4885USP30 1574/4885HPGDS 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.